WO2013037841A3 - Genomes lentiviraux chimeriques non- integratifs comme vaccins contre hiv-1 - Google Patents

Genomes lentiviraux chimeriques non- integratifs comme vaccins contre hiv-1 Download PDF

Info

Publication number
WO2013037841A3
WO2013037841A3 PCT/EP2012/067863 EP2012067863W WO2013037841A3 WO 2013037841 A3 WO2013037841 A3 WO 2013037841A3 EP 2012067863 W EP2012067863 W EP 2012067863W WO 2013037841 A3 WO2013037841 A3 WO 2013037841A3
Authority
WO
WIPO (PCT)
Prior art keywords
retrovirus
chimeric non
against hiv
vaccines against
nucleic acid
Prior art date
Application number
PCT/EP2012/067863
Other languages
English (en)
Other versions
WO2013037841A2 (fr
Inventor
Yahia Chebloune
Delphine ALDEBERT
Original Assignee
Centre National De La Recherche Scientifique (C.N.R.S)
ARRODE-BRUSES, Géraldine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National De La Recherche Scientifique (C.N.R.S), ARRODE-BRUSES, Géraldine filed Critical Centre National De La Recherche Scientifique (C.N.R.S)
Priority to US14/344,360 priority Critical patent/US9879230B2/en
Priority to CN201280055569.7A priority patent/CN103946385B/zh
Priority to MX2014002953A priority patent/MX354571B/es
Priority to EP12756752.7A priority patent/EP2756087A2/fr
Priority to CA2848484A priority patent/CA2848484C/fr
Priority to JP2014530197A priority patent/JP6324892B2/ja
Publication of WO2013037841A2 publication Critical patent/WO2013037841A2/fr
Publication of WO2013037841A3 publication Critical patent/WO2013037841A3/fr
Priority to IL231494A priority patent/IL231494B/en
Priority to ZA2014/02676A priority patent/ZA201402676B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention a pour objet des acides nucléiques comprenant des génomes rétroviraux chimériques non intégratifs comprenant les séquences terminales répétées (LTR) 5' et 3' du lentivirus caprin : virus de l'Arthrite-Encéphalite Caprine (CAEV) ou d'un autre rétrovirus ne s'intégrant pas dans les cellules humaines et au moins un gène viral d'un autre rétrovirus. L'invention concerne également un vecteur comprenant un tel acide nucléique, une composition immunogène ou vaccinale comprenant ledit vecteur ou ledit acide nucléique, ainsi que leur utilisation pour le traitement et/ou la prévention d'une infection par un rétrovirus ou une maladie induite par un agent pathogène.
PCT/EP2012/067863 2011-09-12 2012-09-12 Génomes lentiviraux chimériques non-intégratifs comme vaccins innovants contre le hiv-1 WO2013037841A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US14/344,360 US9879230B2 (en) 2011-09-12 2012-09-12 Chimeric non-integrating lentiviral genomes as vaccines against HIV-1
CN201280055569.7A CN103946385B (zh) 2011-09-12 2012-09-12 作为对抗hiv-1的疫苗的嵌合非整合型慢病毒基因组
MX2014002953A MX354571B (es) 2011-09-12 2012-09-12 Genomas lentivirales quimericos no integrativos como vacunas innovadoras contra el virus de la inmunodeficiencia humana tipo 1 (vih-1).
EP12756752.7A EP2756087A2 (fr) 2011-09-12 2012-09-12 Genomes lentiviraux chimeriques non-integratifs comme vaccins contre hiv-1
CA2848484A CA2848484C (fr) 2011-09-12 2012-09-12 Genomes lentiviraux chimeriques non integratifs comme vaccins innovants contre le hiv-1
JP2014530197A JP6324892B2 (ja) 2011-09-12 2012-09-12 Ｈｉｖ−１に対する革新的ワクチンとしての非組み込み型キメラレンチウイルスゲノム
IL231494A IL231494B (en) 2011-09-12 2014-03-12 Lentiviral genome without chimeric integration as components against hiv-1
ZA2014/02676A ZA201402676B (en) 2011-09-12 2014-04-11 Chimeric non-integrating lentiviral genomes as vaccines against hiv-1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1158096A FR2979919B1 (fr) 2011-09-12 2011-09-12 Genomes lentiviraux chimeriques non-integratifs comme vaccins innovants contre vih-1
FR1158096 2011-09-12

Publications (2)

Publication Number Publication Date
WO2013037841A2 WO2013037841A2 (fr) 2013-03-21
WO2013037841A3 true WO2013037841A3 (fr) 2013-05-23

Family

ID=46829786

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/067863 WO2013037841A2 (fr) 2011-09-12 2012-09-12 Génomes lentiviraux chimériques non-intégratifs comme vaccins innovants contre le hiv-1

Country Status (10)

Country Link
US (1) US9879230B2 (fr)
EP (1) EP2756087A2 (fr)
JP (1) JP6324892B2 (fr)
CN (1) CN103946385B (fr)
CA (1) CA2848484C (fr)
FR (1) FR2979919B1 (fr)
IL (1) IL231494B (fr)
MX (1) MX354571B (fr)
WO (1) WO2013037841A2 (fr)
ZA (1) ZA201402676B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016258929B2 (en) 2015-05-04 2020-10-08 Epivax, Inc. Modified H7 hemagluttinin glycoprotein of the influenza A/Shanghai/2/2013 H7 sequence
JP2018517405A (ja) * 2015-05-04 2018-07-05 エピバックス インコーポレーテッド インフルエンザａ／上海／２／２０１３ ｈ７配列の改変ｈ７赤血球凝集素糖タンパク質
DE102016122316A1 (de) * 2015-11-24 2017-05-24 Glaxosmithkline Intellectual Property Development Limited Stabile zelllinien für retrovirale produktion

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995025806A2 (fr) * 1994-03-24 1995-09-28 Syngenix Limited Lentivirus a encapsidation deficiente
WO2005027844A2 (fr) * 2003-09-16 2005-03-31 University Of Kansas Medical Center Compositions issues d'un vaccin adn et leurs procedes d'utilisation
WO2006074963A2 (fr) * 2005-01-17 2006-07-20 Geneering Gmbh Systeme de transfert de gene lentiviral pour une reparation de l'arn mediee par les ribozymes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US6602505B2 (en) * 1998-04-30 2003-08-05 University Of Southern California Viral chimeras comprised of CAEV and HIV-1 genetic elements

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995025806A2 (fr) * 1994-03-24 1995-09-28 Syngenix Limited Lentivirus a encapsidation deficiente
WO2005027844A2 (fr) * 2003-09-16 2005-03-31 University Of Kansas Medical Center Compositions issues d'un vaccin adn et leurs procedes d'utilisation
WO2006074963A2 (fr) * 2005-01-17 2006-07-20 Geneering Gmbh Systeme de transfert de gene lentiviral pour une reparation de l'arn mediee par les ribozymes

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
A BOUZAR ET AL: "Specific G2 arrest of caprine cells infected with a caprine arthritis encephalitis virus expressing vpr and vpx genes from simian immunodeficiency virus", VIROLOGY, vol. 309, no. 1, 25 April 2003 (2003-04-25), pages 41 - 52, XP055024984, ISSN: 0042-6822, DOI: 10.1016/S0042-6822(03)00014-X *
BERKOWITZ R D ET AL: "Gene transfer systems derived from Visna virus: Analysis of virus production and infectivity", VIROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 279, no. 1, 5 January 2001 (2001-01-05), pages 116 - 129, XP002375761, ISSN: 0042-6822, DOI: 10.1006/VIRO.2000.0659 *
BOUZAR A B ET AL: "Simian immunodeficiency virus Vpr/Vpx proteins kill bystander noninfected CD4+ T-lymphocytes by induction of apoptosis", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 326, no. 1, 15 August 2004 (2004-08-15), pages 47 - 56, XP004521465, ISSN: 0042-6822, DOI: 10.1016/J.VIROL.2004.05.016 *
BOUZAR ET AL: "Activation/proliferation and apoptosis of bystander goat lymphocytes induced by a macrophage-tropic chimeric caprine arthritis encephalitis virus expressing SIV Nef", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 364, no. 2, 7 June 2007 (2007-06-07), pages 269 - 280, XP022106635, ISSN: 0042-6822, DOI: 10.1016/J.VIROL.2007.02.032 *
Conference on AIDS Vaccine; Bangkok, THAILAND; September 12 -15, 2011 *
G. ARRODE-BRUSES ET AL: "Characterization of T-Cell Responses in Macaques Immunized with a Single Dose of HIV DNA Vaccine", JOURNAL OF VIROLOGY, vol. 84, no. 3, 1 February 2010 (2010-02-01), pages 1243 - 1253, XP055024973, ISSN: 0022-538X, DOI: 10.1128/JVI.01846-09 *
G. ARRODE-BRUSES ET AL: "Novel Non-Integrative One-Cycle Lentiviral Genomes Derived from a Naturally Attenuated Animal Lentivirus as HIV Vaccines", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 27, no. 10, October 2011 (2011-10-01), pages A106.P11, XP002674303 *
GÉRALDINE ARRODE-BRUSÉS ET AL: "Immunogenicity of a lentiviral-based DNA vaccine driven by the 5'LTR of the naturally attenuated caprine arthritis encephalitis virus (CAEV) in mice and macaques", VACCINE, vol. 30, no. 19, 2 March 2012 (2012-03-02), pages 2956 - 2962, XP055024459, ISSN: 0264-410X, DOI: 10.1016/j.vaccine.2012.02.050 *
JIN YUHAI ET AL: "Changes of biological properties and pathogenesis of CAEV chimeras expressing Nef and Vpx/Vpr accessory proteins in infected goats", RETROVIROLOGY, BIOMED CENTRAL LTD., LONDON, GB, vol. 6, no. Suppl 2, 24 September 2009 (2009-09-24), pages P22, XP021059480, ISSN: 1742-4690, DOI: 10.1186/1742-4690-6-S2-P22 *
LIU Z ET AL: "Immunoprophylaxis against AIDS in macaques with a lentiviral DNA vaccine", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 351, no. 2, 1 August 2006 (2006-08-01), pages 444 - 454, XP024896459, ISSN: 0042-6822, [retrieved on 20060801], DOI: 10.1016/J.VIROL.2006.03.033 *
U. ZEILFELDER ET AL: "Properties of Wild-Type, C-Terminally Truncated, and Chimeric Maedi-Visna Virus Glycoprotein and Putative Pseudotyping of Retroviral Vector Particles", JOURNAL OF VIROLOGY, vol. 75, no. 1, 1 January 2001 (2001-01-01), pages 548 - 555, XP055056513, ISSN: 0022-538X, DOI: 10.1128/JVI.75.1.548-555.2001 *
Y. CHEBLOUNE, G. ARRODE-BRUSES, M. MOUSSA, D. ALDEBERT: "A novel non integrative a naturally attenuated lentivirus of goats, CAEV, that have constitutive promoters.", J. VACCINES VACCIN, vol. 3, no. 4, 22 August 2012 (2012-08-22), XP002688214 *

Also Published As

Publication number Publication date
EP2756087A2 (fr) 2014-07-23
US9879230B2 (en) 2018-01-30
US20140370051A1 (en) 2014-12-18
WO2013037841A2 (fr) 2013-03-21
CN103946385B (zh) 2016-03-16
IL231494B (en) 2018-05-31
IL231494A0 (en) 2014-04-30
ZA201402676B (en) 2015-05-27
JP2014527812A (ja) 2014-10-23
CA2848484C (fr) 2021-03-23
CN103946385A (zh) 2014-07-23
MX2014002953A (es) 2014-07-10
MX354571B (es) 2018-03-12
FR2979919A1 (fr) 2013-03-15
CA2848484A1 (fr) 2013-03-21
FR2979919B1 (fr) 2015-12-11
JP6324892B2 (ja) 2018-05-16

Similar Documents

Publication Publication Date Title
WO2017058658A3 (fr) Méthodes et compositions pour le traitement guidé par arn de l'infection par le vih
WO2011147590A3 (fr) Recombinase mise au point sur mesure pour recombiner des sites asymétriques voulus dans une pluralité de souches de rétrovirus
EA201890999A1 (ru) Вакцина против вируса простого герпеса
EA201591287A1 (ru) Вакцины, содержащие стабилизированные тримеры оболочки вируса иммунодефицита человека, и способы их применения
EA201600226A1 (ru) Способы и композиции для рнк-направленного лечения вич-инфекции
NZ602504A (en) Antiviral vaccines with improved cellular immunogenicity
WO2016196539A3 (fr) Méthodes et compositions pour le traitement guidé par arn de l'infection par le vih
JP2012509340A5 (fr)
ZA200701176B (en) Vaccines against aids comprising CMV/R-nucleic acid constructs
ATE546540T1 (de) Verwendung massgeschneiderter rekombinasen zur behandlung von retrovirusinfektionen
WO2013070776A8 (fr) Anticorps neutralisant la gp41 et leur utilisation
EP4043031A3 (fr) Constructions à base d'antigènes du virus zika
WO2013110818A3 (fr) Immunogènes pour la vaccination contre le vih
MX2014014683A (es) Peptidos derivados de proteinas virales para usarse como inmunogenos y reactivos de dosificacion.
WO2012115474A3 (fr) Nouvelles souches du virus de varicella-zoster, et vaccin contre la varicelle et le virus de l'herpès-zoster les utilisant
EA201290956A1 (ru) Вакцина против вич
SG178909A1 (en) Generation of a broad t-cell response in humans against hiv
HRP20171697T1 (hr) Varijanta hiv gp-120
AU2017261706A1 (en) Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process
WO2013037841A3 (fr) Genomes lentiviraux chimeriques non- integratifs comme vaccins contre hiv-1
WO2012116142A3 (fr) Gp96-ig-vis/vih combinée d'origine cellulaire, vaccination par protéine gp120 recombinante pour protection contre le vis/vih
WO2011038473A8 (fr) Méthode, trousse, plasmide et composition pour induire une réponse immunitaire contre le virus de la dengue, au moyen de vaccins à adn et de virus chimériques
WO2016106107A3 (fr) Compositions de vaccin contre le virus de la dengue et procédés pour les utiliser
WO2009126308A3 (fr) Compositions et procédés destinés à la production de vaccins et de virus
WO2007137591A3 (fr) Vaccin contre le vih

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201280055569.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12756752

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2014530197

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2848484

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 231494

Country of ref document: IL

Ref document number: MX/A/2014/002953

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2012756752

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 14344360

Country of ref document: US